Document 0644
 DOCN  M94A0644
 TI    In vitro activity of protease inhibitors against HIV.
 DT    9412
 AU    Birch C; Tachedjian G; Tyssen D; Grobelny D; Virology Department, NCHVR,
       Fairfield, Victoria.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:62 (abstract no. TB2).
       Unique Identifier : AIDSLINE ASHM5/94349011
 AB    HIV encodes a novel aspartyl protease that represents an important
       virus-specific target for inhibitors. We have been studying a series of
       transition state analogue inhibitors designed and synthesised in
       Australia that have potent and specific activity against HIV replication
       in cell culture. (Note: the structure of these compounds will not be
       presented). The inhibitors are active against HIV-1 and HIV-2 in acutely
       and chronically infected cells, working through a mechanism involving
       inhibition of cleavage of p55 to its structural components. As a result,
       virions produced in the presence of these drugs are noninfectious. The
       inhibitors are also active against AZT-resistant HIV and the simian
       immunodeficiency virus, but fail to inhibit feline immunodeficiency
       virus. These results will be presented, along with preliminary details
       on the pharmacokinetics of selected inhibitors.
 DE    Antiviral Agents/*PHARMACOLOGY  Cells, Cultured  Gene Products,
       gag/ANTAGONISTS & INHIB  Human  HIV Protease Inhibitors/*PHARMACOLOGY
       HIV-1/*DRUG EFFECTS  HIV-2/*DRUG EFFECTS  Protein Precursors/ANTAGONISTS
       & INHIB  Virus Replication/*DRUG EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).